Robert Freedman
Concepts (532)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Schizophrenia | 72 | 2020 | 439 | 9.190 |
Why?
| | Choline | 12 | 2024 | 127 | 4.870 |
Why?
| | Evoked Potentials, Auditory | 39 | 2024 | 180 | 3.780 |
Why?
| | Receptors, Nicotinic | 37 | 2013 | 334 | 3.570 |
Why?
| | Nicotinic Agonists | 15 | 2016 | 129 | 3.420 |
Why?
| | Brain | 35 | 2021 | 2664 | 2.640 |
Why?
| | alpha7 Nicotinic Acetylcholine Receptor | 24 | 2016 | 97 | 2.400 |
Why?
| | Hippocampus | 31 | 2013 | 894 | 2.170 |
Why?
| | Psychotic Disorders | 9 | 2021 | 169 | 1.990 |
Why?
| | Prenatal Exposure Delayed Effects | 8 | 2021 | 605 | 1.930 |
Why?
| | Hot Flashes | 7 | 2014 | 87 | 1.910 |
Why?
| | Neural Inhibition | 17 | 2013 | 169 | 1.820 |
Why?
| | Psychiatry | 5 | 2018 | 180 | 1.810 |
Why?
| | Sensory Gating | 8 | 2020 | 45 | 1.810 |
Why?
| | Benzylidene Compounds | 8 | 2013 | 20 | 1.760 |
Why?
| | Schizophrenic Psychology | 19 | 2015 | 94 | 1.740 |
Why?
| | Periodicals as Topic | 5 | 2018 | 208 | 1.690 |
Why?
| | Folic Acid | 4 | 2024 | 185 | 1.600 |
Why?
| | Pregnancy Complications, Infectious | 4 | 2021 | 389 | 1.530 |
Why?
| | Nicotine | 17 | 2013 | 334 | 1.490 |
Why?
| | Fetal Development | 9 | 2024 | 296 | 1.480 |
Why?
| | Pyridines | 8 | 2013 | 506 | 1.330 |
Why?
| | Antidepressive Agents | 3 | 2023 | 235 | 1.260 |
Why?
| | Attention | 18 | 2020 | 426 | 1.250 |
Why?
| | Ketamine | 2 | 2023 | 93 | 1.250 |
Why?
| | Chromosomes, Human, Pair 15 | 16 | 2015 | 55 | 1.230 |
Why?
| | Gestational Age | 6 | 2024 | 902 | 1.180 |
Why?
| | Pursuit, Smooth | 9 | 2007 | 19 | 1.140 |
Why?
| | Maternal Exposure | 2 | 2019 | 188 | 1.090 |
Why?
| | Pregnancy | 18 | 2024 | 6727 | 1.000 |
Why?
| | Acoustic Stimulation | 20 | 2020 | 316 | 0.950 |
Why?
| | Menopause | 4 | 2014 | 319 | 0.950 |
Why?
| | Mental Disorders | 5 | 2021 | 1070 | 0.920 |
Why?
| | Evoked Potentials | 7 | 2020 | 126 | 0.880 |
Why?
| | Child Development | 5 | 2024 | 464 | 0.850 |
Why?
| | Child Behavior | 2 | 2016 | 246 | 0.830 |
Why?
| | Electroconvulsive Therapy | 1 | 2023 | 14 | 0.830 |
Why?
| | Humans | 125 | 2024 | 136750 | 0.820 |
Why?
| | Dietary Supplements | 5 | 2021 | 559 | 0.810 |
Why?
| | Prenatal Care | 4 | 2021 | 288 | 0.790 |
Why?
| | Auditory Perception | 8 | 2004 | 115 | 0.780 |
Why?
| | Body Temperature Regulation | 4 | 2013 | 97 | 0.770 |
Why?
| | Infant, Small for Gestational Age | 1 | 2022 | 91 | 0.760 |
Why?
| | Reflex, Startle | 3 | 2014 | 65 | 0.760 |
Why?
| | Phosphatidylcholines | 3 | 2018 | 147 | 0.730 |
Why?
| | Antipsychotic Agents | 8 | 2008 | 193 | 0.730 |
Why?
| | Micronutrients | 2 | 2021 | 92 | 0.710 |
Why?
| | Infant Behavior | 2 | 2020 | 25 | 0.710 |
Why?
| | Female | 74 | 2024 | 72785 | 0.700 |
Why?
| | Infant, Newborn | 10 | 2024 | 6031 | 0.700 |
Why?
| | Brain Mapping | 6 | 2013 | 504 | 0.670 |
Why?
| | Adult | 55 | 2024 | 37626 | 0.660 |
Why?
| | Smoking | 14 | 2013 | 1620 | 0.650 |
Why?
| | Prefrontal Cortex | 3 | 2016 | 304 | 0.640 |
Why?
| | Neurons | 10 | 2019 | 1587 | 0.630 |
Why?
| | Attention Deficit and Disruptive Behavior Disorders | 2 | 2018 | 62 | 0.630 |
Why?
| | Magnetic Resonance Imaging | 13 | 2013 | 3556 | 0.620 |
Why?
| | Electroencephalography | 11 | 2020 | 430 | 0.610 |
Why?
| | Hallucinogens | 1 | 2021 | 104 | 0.610 |
Why?
| | Male | 79 | 2024 | 67305 | 0.600 |
Why?
| | Editorial Policies | 2 | 2018 | 51 | 0.600 |
Why?
| | Endophenotypes | 2 | 2015 | 21 | 0.600 |
Why?
| | Perceptual Disorders | 3 | 2005 | 23 | 0.600 |
Why?
| | Saccades | 7 | 2007 | 40 | 0.590 |
Why?
| | C-Reactive Protein | 4 | 2022 | 408 | 0.580 |
Why?
| | Nootropic Agents | 2 | 2020 | 27 | 0.570 |
Why?
| | Hydrocortisone | 1 | 2020 | 322 | 0.570 |
Why?
| | Premature Birth | 1 | 2021 | 331 | 0.550 |
Why?
| | Betacoronavirus | 1 | 2020 | 266 | 0.540 |
Why?
| | Problem Behavior | 1 | 2018 | 102 | 0.520 |
Why?
| | Depression | 2 | 2023 | 1397 | 0.520 |
Why?
| | Primary Prevention | 1 | 2018 | 196 | 0.510 |
Why?
| | Image Processing, Computer-Assisted | 6 | 2013 | 752 | 0.500 |
Why?
| | Interneurons | 6 | 2001 | 122 | 0.500 |
Why?
| | Arousal | 6 | 1993 | 155 | 0.500 |
Why?
| | Marijuana Smoking | 1 | 2019 | 249 | 0.490 |
Why?
| | Psychological Trauma | 1 | 2016 | 55 | 0.490 |
Why?
| | Validation Studies as Topic | 1 | 2015 | 22 | 0.480 |
Why?
| | Cognition Disorders | 3 | 2010 | 495 | 0.470 |
Why?
| | Sleep | 4 | 2014 | 753 | 0.470 |
Why?
| | Afferent Pathways | 3 | 2013 | 45 | 0.470 |
Why?
| | Bungarotoxins | 10 | 2008 | 46 | 0.450 |
Why?
| | Amygdala | 1 | 2016 | 191 | 0.450 |
Why?
| | Sleep, REM | 3 | 2006 | 33 | 0.440 |
Why?
| | Genotype | 9 | 2015 | 1914 | 0.440 |
Why?
| | Reaction Time | 7 | 2020 | 412 | 0.430 |
Why?
| | Aggression | 1 | 2016 | 200 | 0.430 |
Why?
| | Teaching | 1 | 2016 | 223 | 0.430 |
Why?
| | Cannabis | 1 | 2021 | 487 | 0.420 |
Why?
| | Eye Movements | 4 | 2013 | 67 | 0.410 |
Why?
| | Sleep Apnea Syndromes | 1 | 2014 | 88 | 0.410 |
Why?
| | Phosphorylcholine | 1 | 2013 | 20 | 0.410 |
Why?
| | Gyrus Cinguli | 4 | 2006 | 86 | 0.400 |
Why?
| | Neural Pathways | 4 | 2010 | 295 | 0.400 |
Why?
| | Mothers | 5 | 2021 | 752 | 0.390 |
Why?
| | Genetic Linkage | 10 | 2012 | 297 | 0.390 |
Why?
| | Neuropsychological Tests | 6 | 2016 | 1022 | 0.380 |
Why?
| | Double-Blind Method | 6 | 2016 | 1982 | 0.380 |
Why?
| | Ocular Motility Disorders | 2 | 2004 | 27 | 0.370 |
Why?
| | Clozapine | 4 | 2004 | 20 | 0.370 |
Why?
| | Cerebral Cortex | 6 | 2006 | 433 | 0.360 |
Why?
| | Autism Spectrum Disorder | 1 | 2016 | 395 | 0.360 |
Why?
| | Emotions | 2 | 2016 | 545 | 0.360 |
Why?
| | Middle Aged | 30 | 2016 | 33225 | 0.340 |
Why?
| | Cognition | 3 | 2016 | 1146 | 0.330 |
Why?
| | Nicotinic Antagonists | 6 | 2008 | 34 | 0.330 |
Why?
| | 5-Hydroxytryptophan | 1 | 2009 | 21 | 0.330 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2009 | 46 | 0.320 |
Why?
| | Schizotypal Personality Disorder | 2 | 2002 | 10 | 0.320 |
Why?
| | Sensation Disorders | 2 | 2007 | 37 | 0.320 |
Why?
| | Dopamine | 7 | 2009 | 303 | 0.310 |
Why?
| | Peer Review, Research | 1 | 2009 | 42 | 0.310 |
Why?
| | Cocaine-Related Disorders | 2 | 2001 | 113 | 0.310 |
Why?
| | Infant | 9 | 2021 | 9395 | 0.310 |
Why?
| | Biomedical Research | 1 | 2015 | 688 | 0.310 |
Why?
| | Fetus | 4 | 2021 | 806 | 0.300 |
Why?
| | Thalamus | 2 | 2007 | 107 | 0.300 |
Why?
| | Mice, Inbred DBA | 4 | 2008 | 200 | 0.300 |
Why?
| | Nitric Oxide Synthase | 2 | 2000 | 240 | 0.290 |
Why?
| | Substance Withdrawal Syndrome | 2 | 2007 | 178 | 0.290 |
Why?
| | Writing | 1 | 2009 | 94 | 0.290 |
Why?
| | Body Temperature | 2 | 2007 | 221 | 0.290 |
Why?
| | Child, Preschool | 6 | 2024 | 10997 | 0.280 |
Why?
| | Sensory Aids | 1 | 2007 | 4 | 0.270 |
Why?
| | Neurons, Afferent | 2 | 1999 | 97 | 0.270 |
Why?
| | Miniaturization | 1 | 2007 | 22 | 0.270 |
Why?
| | Auditory Perceptual Disorders | 3 | 2008 | 8 | 0.270 |
Why?
| | Neostriatum | 1 | 2007 | 33 | 0.270 |
Why?
| | Humidity | 1 | 2007 | 50 | 0.270 |
Why?
| | Equipment and Supplies | 1 | 2007 | 42 | 0.270 |
Why?
| | Learning | 2 | 2009 | 406 | 0.270 |
Why?
| | Synaptic Transmission | 6 | 2024 | 289 | 0.270 |
Why?
| | Contingent Negative Variation | 2 | 2005 | 8 | 0.260 |
Why?
| | Phenotype | 7 | 2018 | 3189 | 0.260 |
Why?
| | Child of Impaired Parents | 2 | 1996 | 41 | 0.250 |
Why?
| | Genetic Markers | 7 | 2012 | 344 | 0.250 |
Why?
| | Acetylcholine | 3 | 2002 | 185 | 0.250 |
Why?
| | Pedigree | 8 | 2009 | 514 | 0.250 |
Why?
| | Ganglionic Stimulants | 1 | 2005 | 14 | 0.250 |
Why?
| | Adrenergic Uptake Inhibitors | 1 | 2005 | 17 | 0.250 |
Why?
| | N-Methyl-3,4-methylenedioxyamphetamine | 1 | 2005 | 12 | 0.250 |
Why?
| | Internship and Residency | 1 | 2016 | 1127 | 0.250 |
Why?
| | Biomarkers | 3 | 2015 | 4145 | 0.240 |
Why?
| | Animals | 34 | 2021 | 36836 | 0.240 |
Why?
| | Genetic Predisposition to Disease | 6 | 2013 | 2412 | 0.240 |
Why?
| | Sensation | 3 | 1991 | 53 | 0.230 |
Why?
| | Galvanic Skin Response | 3 | 2013 | 24 | 0.230 |
Why?
| | Child | 9 | 2021 | 21816 | 0.230 |
Why?
| | Receptors, Cholinergic | 5 | 2009 | 37 | 0.230 |
Why?
| | Time Perception | 1 | 2005 | 28 | 0.230 |
Why?
| | Reference Values | 8 | 2002 | 816 | 0.230 |
Why?
| | Mice, Inbred C3H | 2 | 2001 | 269 | 0.220 |
Why?
| | Sleep Deprivation | 1 | 2006 | 174 | 0.220 |
Why?
| | Cross-Over Studies | 3 | 2016 | 562 | 0.220 |
Why?
| | Young Adult | 5 | 2022 | 13126 | 0.210 |
Why?
| | Norepinephrine | 5 | 1992 | 204 | 0.210 |
Why?
| | Bipolar Disorder | 4 | 2007 | 264 | 0.200 |
Why?
| | Pyramidal Cells | 3 | 2003 | 74 | 0.200 |
Why?
| | Echo-Planar Imaging | 1 | 2002 | 21 | 0.200 |
Why?
| | Homovanillic Acid | 5 | 1990 | 10 | 0.200 |
Why?
| | Promoter Regions, Genetic | 4 | 2003 | 1249 | 0.200 |
Why?
| | Wakefulness | 2 | 2001 | 125 | 0.190 |
Why?
| | Linkage Disequilibrium | 2 | 2009 | 268 | 0.180 |
Why?
| | Hearing Disorders | 1 | 2001 | 8 | 0.180 |
Why?
| | Publishing | 2 | 2016 | 145 | 0.180 |
Why?
| | Rats | 16 | 2002 | 5639 | 0.180 |
Why?
| | Social Problems | 1 | 2021 | 12 | 0.180 |
Why?
| | Vitamin A | 1 | 2021 | 58 | 0.180 |
Why?
| | Phencyclidine | 3 | 1992 | 4 | 0.180 |
Why?
| | Oxygen | 3 | 2013 | 930 | 0.170 |
Why?
| | Reward | 1 | 2023 | 244 | 0.170 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2010 | 2051 | 0.170 |
Why?
| | Vitamin D | 2 | 2021 | 397 | 0.170 |
Why?
| | Frontal Lobe | 3 | 2006 | 149 | 0.170 |
Why?
| | Fatty Acids, Omega-3 | 2 | 2021 | 139 | 0.170 |
Why?
| | Sweating | 2 | 2013 | 40 | 0.170 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 2 | 2004 | 413 | 0.160 |
Why?
| | Gene Expression Regulation | 3 | 2015 | 2605 | 0.160 |
Why?
| | Object Attachment | 1 | 2020 | 42 | 0.160 |
Why?
| | Vitamins | 1 | 2021 | 185 | 0.160 |
Why?
| | Chromosome Mapping | 4 | 2009 | 523 | 0.160 |
Why?
| | Schizophrenia, Childhood | 1 | 1999 | 3 | 0.160 |
Why?
| | Analysis of Variance | 5 | 2008 | 1316 | 0.160 |
Why?
| | Pituitary-Adrenal System | 1 | 2020 | 162 | 0.150 |
Why?
| | Bombesin | 1 | 1999 | 11 | 0.150 |
Why?
| | Psychiatric Status Rating Scales | 4 | 2005 | 547 | 0.150 |
Why?
| | Genetic Variation | 3 | 2003 | 985 | 0.150 |
Why?
| | Alleles | 5 | 2009 | 890 | 0.150 |
Why?
| | Rats, Sprague-Dawley | 8 | 2002 | 2486 | 0.150 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2020 | 197 | 0.150 |
Why?
| | Disease Models, Animal | 8 | 2009 | 4281 | 0.150 |
Why?
| | Maternal Age | 1 | 2019 | 129 | 0.150 |
Why?
| | Logistic Models | 2 | 2022 | 2067 | 0.150 |
Why?
| | Nutritional Status | 1 | 2021 | 344 | 0.150 |
Why?
| | Catecholamines | 3 | 2002 | 98 | 0.150 |
Why?
| | Chromosomes, Human, Pair 6 | 2 | 2013 | 52 | 0.150 |
Why?
| | Risk Factors | 10 | 2021 | 10330 | 0.150 |
Why?
| | RNA, Messenger | 7 | 2006 | 2831 | 0.150 |
Why?
| | DNA Mutational Analysis | 3 | 2013 | 399 | 0.150 |
Why?
| | Stem Cells | 1 | 2002 | 592 | 0.140 |
Why?
| | Psychomotor Performance | 4 | 2005 | 309 | 0.140 |
Why?
| | History, 21st Century | 1 | 2018 | 211 | 0.140 |
Why?
| | Irritable Mood | 1 | 2018 | 50 | 0.140 |
Why?
| | Dentate Gyrus | 1 | 1997 | 37 | 0.140 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2002 | 858 | 0.140 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2012 | 2184 | 0.140 |
Why?
| | Adolescent | 12 | 2017 | 21380 | 0.140 |
Why?
| | Postmortem Changes | 3 | 2006 | 17 | 0.130 |
Why?
| | Family | 4 | 2015 | 664 | 0.130 |
Why?
| | Antidepressive Agents, Tricyclic | 1 | 2017 | 30 | 0.130 |
Why?
| | Urinary Tract Infections | 1 | 2019 | 188 | 0.130 |
Why?
| | Neurocognitive Disorders | 1 | 1996 | 26 | 0.130 |
Why?
| | Electrophysiology | 6 | 2003 | 217 | 0.130 |
Why?
| | Data Interpretation, Statistical | 1 | 1998 | 363 | 0.130 |
Why?
| | Gene Expression | 5 | 2006 | 1500 | 0.130 |
Why?
| | Chewing Gum | 2 | 2007 | 9 | 0.130 |
Why?
| | Skin Temperature | 2 | 2006 | 30 | 0.120 |
Why?
| | Prepulse Inhibition | 1 | 2015 | 8 | 0.120 |
Why?
| | Treatment Outcome | 2 | 2023 | 10747 | 0.120 |
Why?
| | Vanilmandelic Acid | 4 | 1990 | 4 | 0.120 |
Why?
| | Methoxyhydroxyphenylglycol | 4 | 1990 | 13 | 0.120 |
Why?
| | Benzodiazepines | 2 | 2008 | 153 | 0.120 |
Why?
| | Nitric Oxide | 1 | 2000 | 915 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 367 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 358 | 0.120 |
Why?
| | Cell Differentiation | 1 | 2002 | 1982 | 0.120 |
Why?
| | Cerebrovascular Circulation | 2 | 2007 | 241 | 0.120 |
Why?
| | Pandemics | 2 | 2021 | 1615 | 0.110 |
Why?
| | Signal Processing, Computer-Assisted | 2 | 2013 | 143 | 0.110 |
Why?
| | Postmenopause | 2 | 2007 | 365 | 0.110 |
Why?
| | Electromyography | 3 | 2005 | 401 | 0.110 |
Why?
| | Respiratory Tract Infections | 1 | 2019 | 393 | 0.110 |
Why?
| | Snoring | 1 | 2014 | 14 | 0.110 |
Why?
| | Twins | 1 | 1996 | 242 | 0.110 |
Why?
| | Synapsins | 1 | 1993 | 14 | 0.110 |
Why?
| | Synaptophysin | 1 | 1993 | 14 | 0.110 |
Why?
| | Hot Temperature | 2 | 2007 | 390 | 0.110 |
Why?
| | Clonidine | 1 | 2013 | 28 | 0.110 |
Why?
| | Corpus Striatum | 2 | 1992 | 167 | 0.110 |
Why?
| | Cerebellum | 5 | 2002 | 224 | 0.110 |
Why?
| | Sleep Stages | 1 | 1993 | 47 | 0.100 |
Why?
| | Polymorphism, Single-Stranded Conformational | 2 | 2003 | 26 | 0.100 |
Why?
| | Polymorphism, Genetic | 4 | 2009 | 659 | 0.100 |
Why?
| | Brain Tissue Transplantation | 1 | 1992 | 19 | 0.100 |
Why?
| | Fetal Tissue Transplantation | 1 | 1992 | 35 | 0.100 |
Why?
| | Mesencephalon | 1 | 1992 | 66 | 0.100 |
Why?
| | Zinc | 1 | 1995 | 297 | 0.100 |
Why?
| | Perinatal Care | 1 | 2013 | 56 | 0.100 |
Why?
| | Parasympathetic Nervous System | 1 | 1992 | 27 | 0.100 |
Why?
| | Auditory Pathways | 1 | 1992 | 52 | 0.100 |
Why?
| | Estrogen Replacement Therapy | 1 | 2013 | 146 | 0.100 |
Why?
| | Genomics | 1 | 2018 | 788 | 0.100 |
Why?
| | Functional Laterality | 1 | 2013 | 223 | 0.100 |
Why?
| | Heart Rate | 2 | 2007 | 820 | 0.100 |
Why?
| | Immunity | 1 | 2013 | 144 | 0.090 |
Why?
| | Pregnancy Complications | 2 | 2019 | 525 | 0.090 |
Why?
| | Iodine Radioisotopes | 4 | 2001 | 145 | 0.090 |
Why?
| | gamma-Aminobutyric Acid | 3 | 2003 | 198 | 0.090 |
Why?
| | Gene Frequency | 2 | 2005 | 520 | 0.090 |
Why?
| | Inflammation | 2 | 2021 | 2835 | 0.090 |
Why?
| | Stress, Psychological | 1 | 2020 | 1097 | 0.090 |
Why?
| | Severity of Illness Index | 3 | 2015 | 2819 | 0.090 |
Why?
| | United States | 3 | 2018 | 14682 | 0.090 |
Why?
| | Alcoholism | 3 | 2003 | 804 | 0.090 |
Why?
| | Memory | 1 | 2013 | 248 | 0.090 |
Why?
| | Circadian Rhythm | 2 | 2013 | 469 | 0.090 |
Why?
| | Gene Duplication | 3 | 2015 | 68 | 0.090 |
Why?
| | Administration, Oral | 2 | 2005 | 812 | 0.090 |
Why?
| | Blood Pressure | 3 | 2007 | 1774 | 0.090 |
Why?
| | Event-Related Potentials, P300 | 2 | 2003 | 14 | 0.090 |
Why?
| | Time Factors | 4 | 2005 | 6808 | 0.090 |
Why?
| | Aged | 10 | 2015 | 23800 | 0.090 |
Why?
| | Photic Stimulation | 2 | 2002 | 241 | 0.080 |
Why?
| | Case-Control Studies | 4 | 2012 | 3540 | 0.080 |
Why?
| | Genetic Association Studies | 1 | 2012 | 375 | 0.080 |
Why?
| | Mice | 8 | 2009 | 17758 | 0.080 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2014 | 291 | 0.080 |
Why?
| | Electrooculography | 2 | 2001 | 12 | 0.080 |
Why?
| | Education, Distance | 1 | 2009 | 48 | 0.080 |
Why?
| | Alprazolam | 1 | 1988 | 6 | 0.080 |
Why?
| | Sequence Deletion | 1 | 2009 | 183 | 0.080 |
Why?
| | Anxiety Disorders | 1 | 2012 | 374 | 0.080 |
Why?
| | Lorazepam | 1 | 1988 | 27 | 0.070 |
Why?
| | Field Dependence-Independence | 1 | 2008 | 5 | 0.070 |
Why?
| | Diazepam | 1 | 1988 | 35 | 0.070 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 2009 | 91 | 0.070 |
Why?
| | Brief Psychiatric Rating Scale | 1 | 2008 | 6 | 0.070 |
Why?
| | Rats, Inbred Strains | 6 | 1992 | 362 | 0.070 |
Why?
| | Glycols | 1 | 1988 | 7 | 0.070 |
Why?
| | Follow-Up Studies | 2 | 2013 | 5105 | 0.070 |
Why?
| | Evoked Potentials, Somatosensory | 1 | 1988 | 33 | 0.070 |
Why?
| | Risk | 2 | 2002 | 908 | 0.070 |
Why?
| | Dihydro-beta-Erythroidine | 2 | 2008 | 6 | 0.070 |
Why?
| | Cross-Sectional Studies | 1 | 2019 | 5419 | 0.070 |
Why?
| | Quality Improvement | 1 | 2016 | 1162 | 0.070 |
Why?
| | Nerve Net | 2 | 2002 | 256 | 0.070 |
Why?
| | Genes | 2 | 1998 | 230 | 0.070 |
Why?
| | Models, Neurological | 2 | 2000 | 242 | 0.070 |
Why?
| | Prospective Studies | 1 | 2019 | 7572 | 0.070 |
Why?
| | Auditory Cortex | 1 | 2007 | 42 | 0.070 |
Why?
| | Microsatellite Repeats | 2 | 2012 | 168 | 0.070 |
Why?
| | Parkinson Disease | 1 | 1992 | 490 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2013 | 1462 | 0.070 |
Why?
| | Diseases in Twins | 1 | 1988 | 169 | 0.070 |
Why?
| | Depressive Disorder | 1 | 1990 | 379 | 0.060 |
Why?
| | Monitoring, Ambulatory | 1 | 2007 | 87 | 0.060 |
Why?
| | Drug Administration Schedule | 1 | 2008 | 785 | 0.060 |
Why?
| | Drug Interactions | 2 | 2008 | 406 | 0.060 |
Why?
| | Telemetry | 1 | 2005 | 40 | 0.060 |
Why?
| | Genome | 2 | 2006 | 294 | 0.060 |
Why?
| | Sensitivity and Specificity | 2 | 2007 | 1936 | 0.060 |
Why?
| | Memory, Short-Term | 1 | 2008 | 249 | 0.060 |
Why?
| | Menstrual Cycle | 1 | 2006 | 132 | 0.060 |
Why?
| | Cold Temperature | 1 | 2006 | 178 | 0.060 |
Why?
| | Internet | 1 | 2009 | 647 | 0.060 |
Why?
| | Sequence Analysis, DNA | 3 | 2003 | 809 | 0.060 |
Why?
| | Quetiapine Fumarate | 1 | 2004 | 23 | 0.060 |
Why?
| | Dibenzothiazepines | 1 | 2004 | 17 | 0.060 |
Why?
| | Predictive Value of Tests | 2 | 2007 | 2021 | 0.060 |
Why?
| | Statistics as Topic | 1 | 2005 | 307 | 0.060 |
Why?
| | Risperidone | 1 | 2004 | 29 | 0.060 |
Why?
| | Visual Pathways | 1 | 2005 | 55 | 0.060 |
Why?
| | Parietal Lobe | 1 | 2005 | 58 | 0.060 |
Why?
| | Verbal Behavior | 1 | 2004 | 40 | 0.060 |
Why?
| | Area Under Curve | 1 | 2005 | 314 | 0.050 |
Why?
| | Dopamine D2 Receptor Antagonists | 1 | 2003 | 5 | 0.050 |
Why?
| | Dopamine Antagonists | 1 | 2003 | 27 | 0.050 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2005 | 219 | 0.050 |
Why?
| | Single-Blind Method | 1 | 2004 | 282 | 0.050 |
Why?
| | Early Diagnosis | 1 | 2005 | 241 | 0.050 |
Why?
| | Visual Fields | 1 | 2004 | 90 | 0.050 |
Why?
| | Mental Recall | 2 | 1996 | 201 | 0.050 |
Why?
| | Pain Measurement | 1 | 2005 | 521 | 0.050 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 1 | 2004 | 243 | 0.050 |
Why?
| | Head | 1 | 2004 | 105 | 0.050 |
Why?
| | Action Potentials | 6 | 1993 | 493 | 0.050 |
Why?
| | Haloperidol | 1 | 2002 | 34 | 0.050 |
Why?
| | Age of Onset | 2 | 2007 | 518 | 0.050 |
Why?
| | Oxygen Consumption | 1 | 2005 | 695 | 0.050 |
Why?
| | Nerve Tissue Proteins | 1 | 2006 | 595 | 0.050 |
Why?
| | Purkinje Cells | 5 | 1988 | 70 | 0.050 |
Why?
| | Visual Cortex | 1 | 2002 | 70 | 0.050 |
Why?
| | Chromosomes, Human, Pair 13 | 1 | 2001 | 15 | 0.050 |
Why?
| | Radioligand Assay | 1 | 2001 | 48 | 0.050 |
Why?
| | Chromosome Disorders | 2 | 1999 | 43 | 0.050 |
Why?
| | Chromosomes, Human, Pair 20 | 1 | 2001 | 17 | 0.050 |
Why?
| | Chromosomes, Human, Pair 10 | 1 | 2001 | 19 | 0.050 |
Why?
| | Lod Score | 1 | 2001 | 67 | 0.050 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 2001 | 41 | 0.050 |
Why?
| | Exons | 3 | 2015 | 351 | 0.050 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 2001 | 68 | 0.050 |
Why?
| | Cloning, Molecular | 2 | 2000 | 534 | 0.050 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2001 | 55 | 0.050 |
Why?
| | Sex Characteristics | 1 | 2007 | 763 | 0.050 |
Why?
| | Movement | 1 | 2004 | 272 | 0.050 |
Why?
| | Binding, Competitive | 1 | 2001 | 202 | 0.050 |
Why?
| | Chromosome Aberrations | 2 | 1999 | 155 | 0.050 |
Why?
| | Hallucinations | 1 | 2001 | 29 | 0.040 |
Why?
| | Cell Count | 1 | 2001 | 323 | 0.040 |
Why?
| | Nutritional Requirements | 1 | 2021 | 78 | 0.040 |
Why?
| | Fornix, Brain | 1 | 2000 | 6 | 0.040 |
Why?
| | Denervation | 1 | 2000 | 24 | 0.040 |
Why?
| | Family Health | 1 | 2001 | 196 | 0.040 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 2000 | 48 | 0.040 |
Why?
| | Point Mutation | 2 | 1999 | 235 | 0.040 |
Why?
| | Lymphocytes | 1 | 2002 | 393 | 0.040 |
Why?
| | Multifactorial Inheritance | 1 | 2001 | 174 | 0.040 |
Why?
| | Animals, Newborn | 1 | 2002 | 844 | 0.040 |
Why?
| | Blotting, Northern | 2 | 2005 | 200 | 0.040 |
Why?
| | Blotting, Western | 3 | 2005 | 1225 | 0.040 |
Why?
| | Binding Sites | 1 | 2002 | 1301 | 0.040 |
Why?
| | Algorithms | 1 | 2007 | 1688 | 0.040 |
Why?
| | Cocaine | 1 | 2001 | 166 | 0.040 |
Why?
| | Fathers | 1 | 1999 | 50 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2009 | 975 | 0.040 |
Why?
| | Genetic Testing | 1 | 2001 | 453 | 0.040 |
Why?
| | Developmental Disabilities | 1 | 2021 | 262 | 0.040 |
Why?
| | Cell Movement | 1 | 2002 | 968 | 0.040 |
Why?
| | Self Medication | 1 | 1998 | 10 | 0.040 |
Why?
| | Chromatography, High Pressure Liquid | 3 | 1989 | 597 | 0.040 |
Why?
| | Cholinergic Agents | 1 | 1998 | 18 | 0.040 |
Why?
| | Genetics, Population | 1 | 1999 | 209 | 0.040 |
Why?
| | National Institutes of Health (U.S.) | 1 | 1998 | 128 | 0.040 |
Why?
| | Heterozygote | 1 | 1998 | 292 | 0.030 |
Why?
| | Electric Conductivity | 2 | 1998 | 86 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2001 | 1733 | 0.030 |
Why?
| | Chromosomes, Artificial, Yeast | 1 | 1997 | 4 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 1 | 2000 | 558 | 0.030 |
Why?
| | Conditioning, Classical | 2 | 2008 | 102 | 0.030 |
Why?
| | Parents | 2 | 2015 | 1340 | 0.030 |
Why?
| | Memory Disorders | 1 | 1998 | 161 | 0.030 |
Why?
| | Age Factors | 2 | 2006 | 3286 | 0.030 |
Why?
| | Base Sequence | 3 | 2009 | 2179 | 0.030 |
Why?
| | In Situ Hybridization | 2 | 2013 | 316 | 0.030 |
Why?
| | Sensory Thresholds | 1 | 1996 | 26 | 0.030 |
Why?
| | Motor Activity | 2 | 1992 | 717 | 0.030 |
Why?
| | Nerve Fibers | 1 | 1995 | 96 | 0.030 |
Why?
| | Receptors, Glutamate | 1 | 1995 | 25 | 0.030 |
Why?
| | Nerve Growth Factors | 1 | 1995 | 79 | 0.030 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1995 | 345 | 0.030 |
Why?
| | Siblings | 1 | 2015 | 227 | 0.030 |
Why?
| | Placenta | 1 | 2021 | 749 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2007 | 5739 | 0.030 |
Why?
| | Aging | 2 | 1999 | 1863 | 0.030 |
Why?
| | Dyskinesia, Drug-Induced | 1 | 1994 | 12 | 0.030 |
Why?
| | Cholinergic Fibers | 1 | 1993 | 18 | 0.030 |
Why?
| | Horseradish Peroxidase | 1 | 1993 | 28 | 0.030 |
Why?
| | Orientation | 1 | 1994 | 48 | 0.030 |
Why?
| | Neuromuscular Junction | 1 | 1994 | 57 | 0.030 |
Why?
| | Polymerase Chain Reaction | 2 | 1995 | 1059 | 0.030 |
Why?
| | Genetic Engineering | 1 | 1994 | 91 | 0.030 |
Why?
| | Axonal Transport | 1 | 1993 | 27 | 0.030 |
Why?
| | Synaptic Vesicles | 1 | 1993 | 44 | 0.030 |
Why?
| | Chronic Disease | 1 | 1999 | 1786 | 0.030 |
Why?
| | Temporal Lobe | 1 | 1993 | 91 | 0.030 |
Why?
| | Tissue Banks | 1 | 2013 | 16 | 0.030 |
Why?
| | Habituation, Psychophysiologic | 1 | 1993 | 55 | 0.030 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2013 | 50 | 0.030 |
Why?
| | DNA Probes | 1 | 2013 | 60 | 0.030 |
Why?
| | Nomifensine | 1 | 1992 | 4 | 0.030 |
Why?
| | HLA-A Antigens | 1 | 2013 | 55 | 0.030 |
Why?
| | Poly A | 1 | 1993 | 51 | 0.030 |
Why?
| | Genes, MHC Class I | 1 | 2013 | 35 | 0.030 |
Why?
| | Receptors, sigma | 1 | 1992 | 2 | 0.030 |
Why?
| | Peptides | 1 | 1999 | 981 | 0.020 |
Why?
| | Levodopa | 1 | 1992 | 30 | 0.020 |
Why?
| | Tomography, Emission-Computed | 1 | 1992 | 66 | 0.020 |
Why?
| | Biogenic Monoamines | 1 | 1992 | 16 | 0.020 |
Why?
| | Benzylamines | 1 | 1992 | 41 | 0.020 |
Why?
| | Sympathomimetics | 1 | 1992 | 21 | 0.020 |
Why?
| | Tubocurarine | 1 | 1992 | 4 | 0.020 |
Why?
| | N-Methylaspartate | 1 | 1992 | 40 | 0.020 |
Why?
| | Mecamylamine | 1 | 1992 | 9 | 0.020 |
Why?
| | Gene Expression Profiling | 2 | 2013 | 1772 | 0.020 |
Why?
| | Muscles | 1 | 1994 | 325 | 0.020 |
Why?
| | Parasympatholytics | 1 | 1992 | 12 | 0.020 |
Why?
| | Injections, Intraventricular | 1 | 1992 | 55 | 0.020 |
Why?
| | Microelectrodes | 1 | 1992 | 45 | 0.020 |
Why?
| | Nervous System | 1 | 1992 | 67 | 0.020 |
Why?
| | Physical Chromosome Mapping | 1 | 2012 | 20 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2002 | 7593 | 0.020 |
Why?
| | Temperature | 1 | 1995 | 674 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 346 | 0.020 |
Why?
| | Genotyping Techniques | 1 | 2012 | 75 | 0.020 |
Why?
| | DNA Replication | 1 | 1993 | 238 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 1997 | 1455 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 1994 | 1350 | 0.020 |
Why?
| | RNA | 2 | 2013 | 921 | 0.020 |
Why?
| | Molecular Sequence Data | 3 | 2003 | 2894 | 0.020 |
Why?
| | Protein Biosynthesis | 1 | 1993 | 430 | 0.020 |
Why?
| | Introns | 2 | 2003 | 256 | 0.020 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 1994 | 404 | 0.020 |
Why?
| | Risk Assessment | 1 | 1999 | 3432 | 0.020 |
Why?
| | Adenylate Cyclase Toxin | 1 | 1989 | 9 | 0.020 |
Why?
| | Virulence Factors, Bordetella | 1 | 1989 | 20 | 0.020 |
Why?
| | Pertussis Toxin | 1 | 1989 | 26 | 0.020 |
Why?
| | Receptors, Dopamine | 1 | 1989 | 20 | 0.020 |
Why?
| | Blotting, Southern | 1 | 2009 | 72 | 0.020 |
Why?
| | Autoanalysis | 1 | 1989 | 8 | 0.020 |
Why?
| | Saccharomyces cerevisiae | 1 | 1994 | 556 | 0.020 |
Why?
| | Adenylyl Cyclases | 1 | 1989 | 87 | 0.020 |
Why?
| | Electrochemistry | 1 | 1989 | 78 | 0.020 |
Why?
| | Odds Ratio | 1 | 2012 | 1065 | 0.020 |
Why?
| | Yohimbine | 1 | 1988 | 10 | 0.020 |
Why?
| | Dioxins | 1 | 1988 | 6 | 0.020 |
Why?
| | Dioxanes | 1 | 1988 | 10 | 0.020 |
Why?
| | GTP-Binding Proteins | 1 | 1989 | 161 | 0.020 |
Why?
| | Cell Line | 2 | 2009 | 2838 | 0.020 |
Why?
| | Gene Dosage | 1 | 2009 | 140 | 0.020 |
Why?
| | Receptors, Adrenergic | 1 | 1988 | 33 | 0.020 |
Why?
| | Tyramine | 1 | 1988 | 8 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2009 | 317 | 0.020 |
Why?
| | Pulse | 1 | 1988 | 23 | 0.020 |
Why?
| | Fluphenazine | 1 | 1987 | 5 | 0.020 |
Why?
| | Saliva | 1 | 1989 | 242 | 0.020 |
Why?
| | Tobacco Use Disorder | 1 | 2010 | 251 | 0.020 |
Why?
| | Stereoisomerism | 1 | 1987 | 96 | 0.020 |
Why?
| | Audiometry, Evoked Response | 1 | 1987 | 12 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2008 | 431 | 0.020 |
Why?
| | Autoradiography | 2 | 1997 | 78 | 0.020 |
Why?
| | Tyrosine | 1 | 1988 | 222 | 0.020 |
Why?
| | Mutation | 2 | 2015 | 3947 | 0.020 |
Why?
| | Task Performance and Analysis | 1 | 2007 | 183 | 0.020 |
Why?
| | Depressive Disorder, Major | 1 | 2010 | 362 | 0.020 |
Why?
| | ROC Curve | 1 | 2007 | 544 | 0.020 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2006 | 37 | 0.020 |
Why?
| | alpha Catenin | 1 | 2005 | 11 | 0.020 |
Why?
| | Transcription Factors | 1 | 1994 | 1718 | 0.020 |
Why?
| | Suicide | 1 | 1993 | 645 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2005 | 116 | 0.010 |
Why?
| | Patient Selection | 1 | 2009 | 691 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2006 | 560 | 0.010 |
Why?
| | Nervous System Diseases | 1 | 1987 | 263 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2007 | 1480 | 0.010 |
Why?
| | Fourier Analysis | 1 | 2002 | 40 | 0.010 |
Why?
| | Genome-Wide Association Study | 1 | 2009 | 1428 | 0.010 |
Why?
| | Artifacts | 1 | 2002 | 129 | 0.010 |
Why?
| | Sex Factors | 1 | 2006 | 2064 | 0.010 |
Why?
| | Diet | 1 | 1988 | 1274 | 0.010 |
Why?
| | Contig Mapping | 1 | 1998 | 11 | 0.010 |
Why?
| | Genes, Duplicate | 1 | 1998 | 4 | 0.010 |
Why?
| | Restriction Mapping | 1 | 1998 | 77 | 0.010 |
Why?
| | Receptors, Presynaptic | 1 | 1998 | 10 | 0.010 |
Why?
| | Models, Biological | 1 | 2005 | 1773 | 0.010 |
Why?
| | Macaca radiata | 1 | 1997 | 16 | 0.010 |
Why?
| | Autopsy | 1 | 1997 | 93 | 0.010 |
Why?
| | Organ Specificity | 1 | 1997 | 304 | 0.010 |
Why?
| | Mice, Inbred Strains | 1 | 1996 | 409 | 0.010 |
Why?
| | Species Specificity | 1 | 1996 | 586 | 0.010 |
Why?
| | Cell Adhesion Molecules, Neuronal | 1 | 1995 | 41 | 0.010 |
Why?
| | Gene Amplification | 1 | 1995 | 104 | 0.010 |
Why?
| | Isomerases | 1 | 1994 | 8 | 0.010 |
Why?
| | Protein Disulfide-Isomerases | 1 | 1994 | 11 | 0.010 |
Why?
| | Genes, Fungal | 1 | 1994 | 52 | 0.010 |
Why?
| | tau Proteins | 1 | 1995 | 88 | 0.010 |
Why?
| | DNA Primers | 1 | 1995 | 514 | 0.010 |
Why?
| | Endopeptidases | 1 | 1994 | 90 | 0.010 |
Why?
| | Cadaver | 1 | 1995 | 296 | 0.010 |
Why?
| | Molecular Biology | 1 | 1994 | 58 | 0.010 |
Why?
| | Glycosylation | 1 | 1994 | 151 | 0.010 |
Why?
| | Fungal Proteins | 1 | 1994 | 123 | 0.010 |
Why?
| | Genetic Vectors | 1 | 1994 | 317 | 0.010 |
Why?
| | DNA | 1 | 1998 | 1458 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1994 | 2138 | 0.010 |
Why?
| | Idazoxan | 1 | 1988 | 1 | 0.000 |
Why?
| | Phentolamine | 1 | 1988 | 15 | 0.000 |
Why?
| | Receptors, Adrenergic, alpha | 1 | 1988 | 26 | 0.000 |
Why?
| | Rats, Inbred F344 | 1 | 1988 | 264 | 0.000 |
Why?
| | Desipramine | 1 | 1988 | 9 | 0.000 |
Why?
| | Receptors, Adrenergic, beta | 1 | 1988 | 127 | 0.000 |
Why?
| | Magnesium | 1 | 1987 | 156 | 0.000 |
Why?
| | DNA-Binding Proteins | 1 | 1994 | 1501 | 0.000 |
Why?
|
|
Freedman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|